State of the art in the pharmacologic treatment of borderline personality disorder

Current Psychiatry Reports

Volumn 13, Issue 1, 2011, Pages 69-75

  Feurino III, Louis ^a   Silk, Kenneth R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Atypical antipsychotics; Borderline personality disorder; Mood stabilizers; Pharmacotherapy; Psychopharmacology; SSRIs; Systematic reviews

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLONIDINE; DULOXETINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ANXIETY; ARTICLE; BEHAVIOR THERAPY; BORDERLINE STATE; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; EVENING DOSAGE; HUMAN; MONOTHERAPY; MORNING DOSAGE; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PSYCHOTHERAPY; TREATMENT RESPONSE;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 79551519244     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0168-9     Document Type: Article

References (44)

1. PH Soloff 1981 Pharmacotherapy of borderline disorders Compr Psychiatry 22 535 543 1:STN:280:DyaL38%2FntFarsw%3D%3D 10.1016/0010-440X(81)90001-8 6118234
2. MC Zanarini FR Frankenburg GS Khera J Bleichmar 2001 Treatment histories of borderline inpatients Compr Psychiatry 42 144 150 1:STN:280: DC%2BD3MzmvVGmtQ%3D%3D 10.1053/comp.2001.19749 11244151 (Pubitemid 32207250)
3. JM Oldham DS Bender AE Skodol, et al. 2004 Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder J Psychiatr Pract 10 156 161 10.1097/00131746-200405000- 00003 15330221 (Pubitemid 38669723)
4. E Baker-Glenn M Steels C Evans 2010 Use of psychotropic medication among psychiatric out-patients with personality disorder The Psychiatrist 34 83 86 10.1192/pb.bp.108.021758
5. •• Stoffers J, Völlm BA, Rücker G, et al.: Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010, 6:CD005653. This is the full Cochrane systematic review of the pharmacotherapy of BPD. It is a fascinating and thoroughly detailed document, but it may be easier to digest in the more condensed version by Lieb et al. [29••].
6. •• National Institute for Health and Clinical Excellence (NICE). Borderline Personality Disorder, Treatment and Management. London: The British Psychological Society and The Royal College of Psychiatrists. Available at http://www.nice.org.uk/CG78. Accessed May 1, 2010. As part of the NICE Guideline, this is a thorough review of the psychopharmacologic treatment of BPD. The authors are fairly negative about the usefulness of pharmacologic treatment, but they do give, in the fuller version, guidelines on psychopharmacologic treatment and many details as to how they evaluated the existing literature.
7. American Psychiatric Association 2001 Practice Guideline for the Treatment of Patients with Borderline Personality Disorder Am J Psychiatry 158 1 52 10.1176/appi.ajp.158.1.1 (Pubitemid 32047238)
8. • Schulz SC, Zanarini MC, Bateman A, et. al.: Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008, 193:485-492. This is the largest clinical trial in terms of numbers of participants of BPD pharmacotherapy ever conducted. Unfortunately, the results are not impressive.
9. • Linehan MM, McDavid JD, Brown MZ, et al.: Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008, 69:999-1005. This study combined dialectical behavioral therapy plus medication or placebo. It re-creates clinical reality, in which most patients receive pharmacotherapy as well as psychosocial (psychotherapeutic) treatment. Both groups improved, and the active medication group improved more (but not significantly more) quickly.
10. SS Shafti B Shahveisi 2010 Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial J Clin Psychopharm 30 44 47 1:CAS:528:DC%2BC3cXlvFalsA%3D%3D 10.1097/JCP. 0b013e3181c826ff
11. • Pascual JC, Soler J, Puigdemont D, et al.: Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008, 69:603-608. This is a negative study for an atypical antipsychotic. The only solidly positive RCT for an atypical antipsychotic is with aripiprazole (Nickel et al. [44]), with some contradictory evidence for olanzapine.
12. Loew TH, Nickel MK, Muehlbacher M, et. al.: Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharm 2006, 26:61-66. (Pubitemid 43167093)
13. • Nickel MK, Loew TH: Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry 2008, 23:115-117. This study complements this group's previous study showing the effectiveness of topiramate in women.
14. • Reich DB, Zanarini MC, Bieri KA: A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharm 2009, 24:270-275. This is another study that supports the effectiveness of mood stabilizers in the BPD population.
15. • Ziegenhorn AA, Roepke S, Schommer NC, et.al. : Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharma 2009, 29:170-173. This is an intriguing study that revealed the effectiveness of clonidine. However, the effectiveness seemed restricted to patients who also had comorbid PTSD.
16. MC Zanarini AA Vujanovic EA Parachini, et al. 2003 Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology J Personal Disord 17 233 142 10.1521/pedi.17.3.233. 22147 (Pubitemid 36741563)
17. MP Bogenschutz 2004 George Nurnberg H: Olanzapine versus placebo in the treatment of borderline personality disorder J Clin Psychiatry 65 104 109 1:CAS:528:DC%2BD2cXhs12qsbs%3D 10.4088/JCP.v65n0118 14744178
18. E Villeneuve S Lemelin 2005 Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target J Clin Psychiatry 66 1298 303 1:CAS:528:DC%2BD2MXht1aqs7zN 10.4088/JCP.v66n1013 16259544
19. S Bellino E Paradiso F Bogetto 2006 Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study J Clin Psychiatry 67 1042 1046 1:CAS:528:DC%2BD28XoslGis7g%3D 10.4088/JCP.v67n0705 16889446
20. Adityanjee A Romine E Brown 2008 Quetiapine in patients with borderline personality disorder: an open-label trial Ann Clin Psychiatry 20 226
21. F Van den Eynde V Senturk K Naudts, et al. 2008 Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder J Clin Psychopharm 28 147 155 10.1097/JCP.0b013e318166c4bf (Pubitemid 351417119)
22. FM Quitkin 1999 Placebos, drug effects, and study design: a clinician's guide Am J Psychiatry 156 829 836 1:STN:280:DyaK1M3ovVeqsw%3D%3D 10360119
23. S Bellino M Zizza C Rinaldi F Bogetto 2006 Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy Can J Psychiatry 51 453 460 16838827
24. • Bellino S, Rinaldi C, Bogetto F: Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy Can J Psychiatry 2010, 55:74-81. This is another study (though open-label) exploring the effectiveness of combined psychotherapy and psychopharmacology. Length of treatment seemed to be the most important variable related to improvement.
25. S Bellino E Paradiso P Bozzatello F Bogetto 2010 Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study J Psychopharm 24 333 339 1:CAS:528:DC%2BC3cXkslSgurw%3D 10.1177/0269881108095715
26. A Arntz M van den Hoorn J Cornelis, et al. 2003 Reliability and validity of the borderline personality disorder severity index J Person Disord 17 45 59 10.1521/pedi.17.1.45.24053 (Pubitemid 36343239)
27. T Miyaoka M Furuya H Yasuda, et al. 2008 Yi-gan san for the treatment of borderline personality disorder: an open-label study Prog Neuropsychopharmacol Biol Psychiatry 32 150 154 10.1016/j.pnpbp.2007.07.026 17765378
28. CA Binks M Fenton L McCarthy, et al. 2006 Pharmacological interventions for people with borderline personality disorder Cochrane Database Syst Rev 25 CD005653
29. •• Lieb K, Völlm B, Rücker G, et al.: Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010, 196:4-12. This is the shorter, more concise, more accessible version of the Cochrane review (Stoffers et al. [5••]).
30. PF Abraham JR Calabrese 2008 Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 111 21 30 1:CAS:528:DC%2BD1cXhtFylsrrJ 10.1016/j.jad.2008.01.024 18304647
31. M Nosè A Cipriani B Biancosino, et al. 2006 Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials Int Clin Psychopharm 21 345 353 10.1097/01.yic.0000224784.90911.66 (Pubitemid 44498276)
32. SC Herpertz M Zanarini CS Schulz, et al. 2007 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders World J Biol Psychiatry 8 212 244 10.1080/ 15622970701685224 17963189 (Pubitemid 350018476)
33. •• Mercer D, Douglass AB, Links PS: Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord 2009, 23:156-174. This is an excellent meta-analysis that limited itself to studying the outcomes for depression and anger symptoms. Mood stabilizers had the largest effect on anger, with a moderate effect on depression. Antidepressants had a moderate effect on anger but only a small effect on depression. Antipsychotics (particularly aripiprazole) had a moderate effect on anger but no effect on depression. It is worth comparing these results with those of Ingenhoven et al. [35•].
34. C Duggan N Huband N Smailagic, et al. 2008 The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials Personality Ment Health 2 119 170 10.1002/pmh.41
35. • Ingenhoven T, Lafay P, Rinne T, et al.: Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 2010, 71:14-25. This excellent meta-analysis found that antipsychotics have a moderate effect on cognitive-perceptual symptoms and a moderate to large effect on anger, while antidepressants have no significant effect on impulsivity or depressed mood but a small effect on anxiety and anger. Mood stabilizers had a very large effect on impulsivity, a large effect on anxiety, and a moderate effect on depressed mood. This study provides support for mood stabilizer use in BPD patients, and it is worth comparing and contrasting it with the Mercer et al. [33••] meta-analysis.
36. • Díaz-Marsá M, González Bardanca S, Tajima K, et al.: Psychopharmacological treatment in borderline personality disorder. Actas Esp Psiquiat.2008, 36:39-49. This is a very thorough review that proposes updated algorithms for the pharmacologic treatment of the following temperamental dimensions found in BPD: impulsivity-aggression, emotion instability, cognitive-perceptual distortions, and anxiety-inhibition. It is in English.
37. EFH Saunders K Silk 2009 Personality trait dimensions and the pharmacologic treatment of borderline personality disorder J Clin Psychopharm 29 461 267 10.1097/JCP.0b013e3181b2b9f3
38. Silk KR, Jibson MD (2010) Personality disorders. In: Rothschild AJ (ed) The Evidence-Based Guide to Antipsychotic Medications. Washington DC: American Psychiatric Publishing, Inc; 2010, pp 101-124
39. MC Zanarini B Stanley DW Black, et al. 2010 Methodological considerations treatment trials for persons personality disorder Ann Clin Psychiatry 22 75 83 20445834
40. MC Zanarini FR Frankenburg CJ DeLuca, et al. 1998 The pain of being borderline: dysphoric states specific to borderline personality disorder Harvard Rev Psychiatry 6 201 207 1:STN:280:DyaK1M3pvVGrsQ%3D%3D 10.3109/ 10673229809000330
41. Silk KR, Jibson MD: Personality disorders. In The Evidence-Based Guide to Antidepressant Medications. Edited by Rothschild AJ. Washington DC: American Psychiatric Publishing, Inc; Inc; 2011, In press.
42. Bateman A, Zanarini MC: Personality disorders. In Cambridge Textbook of Effective Treatments in Psychiatry. Edited by Tyrer P, Silk KR. Cambridge, UK: Cambridge University Press; 2008, pp 659-681.
43. T Rinne W van den Brink 2002 Wouters L, et al. : SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder Am J Psychiatry 159 2048 2054 10.1176/appi.ajp.159.12.2048 12450955 (Pubitemid 35423864)
44. MK Nickel M Muehlbacher C Nickel, et al. 2006 Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study Am J Psychiatry 163 833 838 10.1176/appi.ajp.163.5.833 16648324 (Pubitemid 44464531)